Principia Biopharma Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|
| Revenue | $5.2M | $11.4M | $5.2M | $0 |
| Operating income | −$14.9M | $532,000 | −$26.6M | −$27.1M |
| Net income | — | $310,000 | −$9.9M | −$30.6M |
| Total assets | $382.7M | $195.5M | $43.5M | — |
| Total liabilities | — | $25.7M | $58.4M | — |
| Equity | $359.0M | $169.9M | −$143.5M | −$116.7M |
| EPS (diluted) | $-0.57 | $0.00 | $-50.37 | $-59.89 |
| Shares out. | 23.9M | 23.9M | 626,613 | 511,597 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −288.2%
- Net margin
- —
- Return on equity
- —
- Return on assets
- —
- Return on capital (ROCE)
- −4.1%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $15.04
- Revenue growth (YoY)
- −54.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 0 good- Operating losses (negative operating margin)
- Revenue declined year-over-year
- Negative operating cash flow
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsSep 28, 2020
- Entered a material agreement · Director / officer change · Other material eventAug 17, 2020
- Results of operationsAug 6, 2020
- Other material eventJun 26, 2020
- Other material eventJun 12, 2020
- Shareholder voteJun 9, 2020
- Results of operationsMay 6, 2020
- Other material eventApr 24, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 16, 2021
- 15-12BOct 8, 2020
- SC 13D/AAMENDMENT TO FORM SC 13DOct 1, 2020
- EFFECTSep 29, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
- 4FORM 4 SUBMISSIONSep 28, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.